How Johnson & Johnson beat expectations in Q1

The healthcare giant saw a marked recovery from the negative impacts of the COVID-19 pandemic.

| More on:
Covid-19 vaccine

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Johnson & Johnson (NYSE: JNJ) has been in the news quite a bit recently. And not for good reasons. The healthcare giant's COVID-19 vaccine is still on pause in the U.S. due to concerns about rare blood clotting issues. A key facility where the vaccine is manufactured has been temporarily shut down while the U.S. Food and Drug Administration (FDA) conducts an inspection.

However, the company recently saw some good news for a change. Johnson & Johnson announced its first-quarter results before the market opened on Tuesday. Here are the highlights from J&J's Q1 update. 

By the numbers

Johnson & Johnson reported revenue in the first quarter of $22.3 billion, an 8% year-over-year jump. This topped the average analysts' revenue estimate of $22.01 billion.

The company announced Q1 net income of $6.2 billion, or $2.32 per share, based on generally accepted accounting principles (GAAP). J&J's GAAP earnings totaled $5.8 billion, or $2.17 per share, in the prior-year period. 

There was a similar improvement on a non-GAAP basis. Johnson & Johnson posted adjusted net income in the first quarter of $6.9 billion, or $2.59 per share. In the prior-year period, the company's adjusted earnings came in at $6.2 billion, or $2.30 per share. J&J also handily beat the consensus analysts' adjusted earnings estimate of $2.34 per share.

Behind the numbers

The best story for Johnson & Johnson in the first quarter came from its medical devices segment. This business was significantly impacted by COVID-19 in 2020. However, sales for the segment jumped 10.9% to nearly $6.6 billion as the medical device market recovered from the pandemic.

J&J's biggest segment also delivered a solid performance in the first quarter. Pharmaceutical segment revenue rose 9.6% to $12.2 billion. Sales increased 7.4% on an operational basis excluding the net impact of acquisitions and divestitures.

This growth was driven by several drugs with especially fast-rising sales. Multiple myeloma drug Darzalex topped the list with Q1 sales soaring 45.6% year over year to nearly $1.4 billion. Autoimmune disease drugs Stelara and Tremfya also were big winners, with sales jumping 18.1% to $2.1 billion and 41% to $418 million, respectively.

Johnson & Johnson also reported sales for its COVID-19 vaccine for the first time in the first quarter. Even though the vaccine didn't win U.S. Emergency Use Authorization until late February, it still raked in $100 million during the quarter.

The company's consumer health segment generated revenue of $3.5 billion, down 2.3% year over year. However, this year-over-year comparison was especially challenging because of the boost in sales of over-the-counter products in the first quarter of 2020 as the COVID-19 pandemic began.

Looking ahead

Despite the solid Q1 performance, the healthcare stock slipped a little in early trading on Tuesday. Why? Johnson & Johnson's full-year guidance was a little lower than what analysts expected.

The company now projects sales of $90.6 billion to $91.6 billion for full-year 2021. This range is narrower than the company's guidance provided in January of sales between $90.5 billion and $91.7 billion. J&J expects adjusted full-year earnings per share (EPS) will come in between $9.42 and $9.57. In January, its outlook projected adjusted earnings per share of $9.40 to $9.60.

An advisory committee is scheduled to meet on Friday of this week to review data about the rare blood clotting issues linked to J&J's COVID-19 vaccine. It's possible that the company will receive more good news with a recommendation for the resumption of the administration of the vaccine.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Johnson & Johnson. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Business woman with her arms folded stands in front of multiple screens.
International Stock News

How did the Magnificent 7 fare this reporting season?

Let's explore the highlights.

Read more »

A man looking at his laptop and thinking.
International Stock News

Amazon: A good quarter but some concerns

Here's our initial take on Amazon's financial report.

Read more »

Man looks up at apple on his head.
International Stock News

Apple: Growth in a difficult environment

Here's our initial take on Apple's financial report.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Why Microsoft stock popped this week

Microsoft stock was up by 9.5% this week.

Read more »

Electric vehicle such as Tesla being charged at charging station.
International Stock News

Tesla searches for Musk successor: Why this matters

Could Elon get the chainsaw from his own board?

Read more »

customers inside and outside a Microsoft retail store
International Stock News

Microsoft shares earnings report: What's the verdict?

Investors moved the Microsoft share price significantly.

Read more »

Warren Buffett
International Stock News

Countdown to Berkshire's AGM: What do investors expect to hear from Warren Buffett this year?

All eyes will be on Omaha, Nebraska this weekend.

Read more »

A smiling woman holds a Facebook like sign above her head.
International Stock News

Meta surges on blockbuster earnings report

It's a good day to be a Meta investor.

Read more »